Compare DexCom, Inc. (DXCM) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.77 (market cap $3.14B). The key difference: DexCom, Inc. is far larger — about 10.1× Invesco S&P 500 High Div Low Volatility ETF's market cap, and DexCom, Inc. is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| DXCM | SPHD | |
|---|---|---|
Market Cap | $31.86B | $3.14B |
Volume | 3,607,070 | 1,461,349 |
Sector | Health | — |
52-Week High | $92.34 | $53.55 |
52-Week Low | $54.84 | $46.96 |
Typical Hold Time | 62 Days | 125 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
SPHD trades at $48.19, down 0.58% on the day, with a bearish technical signal driven by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income but facing criticism for weaker total returns compared to peers like SCHD. Recent dividends of $0.20 and $0.21 were declared for 2026, emphasizing its income-oriented strategy.
Outlook is cautious due to underperformance risks and lack of quality filters in stock selection. Opportunities include reliable monthly dividends for retirees, but risks involve yield traps and market volatility. Investors should weigh income needs against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
